Skip Navigation
| 1. | No author listed. Living skin substitute can heal diabetic foot ulcer wounds. FDA Consum. 2000 Sep-Oct; 34(5): 6. |
| 2. | No author listed. Treatment of ulcers with Apligraf. Krankenpfl J. 2002; 40(1-2): 32-3. (Article in German) |
| 3. | Abai B, Thayer D, Glat PM. Two Cases of Traumatic Wounds in Patients with Ehlers-Danlos Syndrome Successfully Treated with A Bioengineered Skin Equivalent. Wounds 2003; 15(6):201-207. |
| 4. | Akopian G, Nunnery SP, Piangenti J, Rankin P, Rinoie C, Lee E, Alexander M. Outcomes of conventional wound treatment in a comprehensive wound center. Am Surg. 2006 Apr;72(4):314-7 |
| 5. | Albrant DH. AphA Drug Treatment Protocols: Management of Foot Ulcers in Patients with Diabetes. J of the American Pharma Assoc., July/August 2000; 40(4): 467-474. |
| 6. | Allie DE, Hebert CJ, Lirtzman MD, Wyatt CH, Keller VA, Souther SM, Allie AA, Mitran EV, Walker CM. Novel treatment strategy for leg and sternal wound complications after coronary artery bypass graft surgery: Bioengineered Apligraf. Ann Thorac Surg. 2004 Aug;78(2):673-8. |
| 7. | Alvarez OM, Fahey CB, Auletta MJ, Fernandez-Obregon A. A novel treatment for venous leg ulcers. J Foot Ankle Surg. 1998 Jul-Aug; 37(4): 319-24. |
| 8. | American Diabetes Association. Consensus Development Conference on Diabetic Foot Wound Care. 7-8 April 1999, Boston, Massachusetts. Diabetes Care, August 1999; 22(8): 1354-1360. |
| 9. | Atillasoy E and Sabolinski ML. Current and investigative uses of Graftskin (Apligaf) in wound care: summary. Wounds, 2000 12(5 Suppl A) 78A-79A. |
| 10. | Attinger CE, et al: Clinical Approach to Wounds: Debridement and Wound Bed Preparation Including the Use of Dressings and Wound-Healing Adjuvants. Plast. Reconstr. Surg. 117 (Suppl.): 72S, 2006. |
| 11. | Badiavas EV, Paquette D, Carson P and Falanga V. Human Chronic Wounds Treated with Bioengineered Skin: Histologic Evidence of Host-Graft Interactions. J Am Acad Dermatol. 2002;46:524-30. |
| 12. | Banta MN, Kirsner RS. Modulating diseased skin with tissue engineering: actinic purpura treated with Apligraf. Dermato.l Surg. 2002 Dec;28(12):1103-6. |
| 13. | Bell, D. Heel ulcer treatment layers practitioner options. Biomechanics Mar 2007 |
| 14. | Bell, E., et al: Living Tissue Formed in vitro and Accepted as Skin-Equivalent Tissue of Full Thickness. Science 211: 1052-1054, 1981 |
| 15. | Bell, E and Rosenberg, M.: The Commercial Use of Cultivated Human Cells. Transplant. Proc. 22:971-974, 1990 |
| 16. | Bell, E., et al: Recipes for Reconstituting Skin. J. Biomech. Eng. 113: 113-119, 1991 |
| 17. | Beless Daniel J, Gelly Helen B., Lynch Robert P. Effects of Living Skin Equivalent on Calciphylaxis-Induced Skin Necrosis Wounds – Case Studies. Wounds 2001 13(4):165-170. |
| 18. | Bello YM, Falabella AF, Schachner LA. Epidermolysis Bullosa and its Treatment. Wounds 2001;13(3):113-118 |
| 19. | Bello YM, Falabella AF. The role of graftskin (Apligraf) in difficult-to-heal venous leg ulcers. J Wound Care. 2002 May;11(5):182-3. |
| 20. | Bello YM, Falabella AF, Eaglstein WH . Tissue-engineered skin. Current status in wound healing. Am J Clin Dermatol. 2001; 2(5): 305-13 |
| 21. | Bilbo PR, Nolte CJM, Oleson MA, Mason VS, Parenteau NL. Skin in Complex Culture: The Transition from "Culture" Phenotype to Organotypic Phenotype. J. Toxicol.-Cut. & Ocular Toxicol., 12(2), 183-196 (1993) |
| 22. | Bogensberger G, Eaglstein W, Kirsner R. Chronic leg ulcers in a patient with combined arterial and venous disease successfully treated with a human skin equivalent: a case report. Wounds, 2000; 12(5):118-121. |
| 23. | Boulton Andrew JM, Kirsner Robert S, Vileikyte Loretta. Neuropathic Diabetic Foot Ulcers. New Engl J Med 2004;351:48-55. |
| 24. | Brem H et al: Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent. A new paradigm in wound healing. Arch Surg 135: 627-634 June 2000 |
| 25. | Brem H, Kirsner R. Use of Graftskin (Apligraf®) in the treatment of pressure ulcers and acute wounds. Wounds, 2000; 12(5Suppl A):72A-77A. |
| 26. | Brem H, Balledux J, Sukkarieh T, Cason, P and Falanga V. Healing of venous ulcers of long duration with a bilayered living skin substitute: results from a general surgery and dermatology department. Dermatol Surg. 27:916-919, 2001. |
| 27. | Brem H, Balledux J, Sukkarieh T, Carson P, Falanga V. Healing of venous ulcers of long duration with a bilayered living skin substitute: results from a general surgery and dermatology department. Dermatol Surg. 2001 Nov; 27(11): 915-9. |
| 28. | Brem H, Nierman DM, Nelson JE. Pressure ulcers in the chronically critically ill patient. Crit Care Clin 18 (2002) 683-694 |
| 29. | Brem H, Young J, Isaacs C, Tomic-Canic M, Ehrlich Paul. Clinical Efficacy and Mechanisms of Bilayered Living Human Skin Equivalent (HSE) in Treatment of Diabetic Foot Ulcers. Surgical Technology International XI May 2003 pp. 23-31. |
| 30. | Brem H et al: Wound Healing Protocols for diabetic foot and pressure ulcers. Surgical Technology International XI May 2003 pp. 85-92. |
| 31. | Brem Harold, Sheehan Peter, Boulton Andrew JM. Protocol for Treatment of Diabetic Foot Ulcers. American Journal of Surgery (Suppl to May 2004) 187: 1S-10S |
| 32. | Brem H, et al: Healing of Elderly Patients with Diabetic Foot ulcers, venous stasis ulcers, and pressure ulcers. Surgical Technology International XI May 2003 pp. 161-167. |
| 33. | Brem H. Protocol for the Successful Treatment of Venous Ulcers. Amer. J. of Surg. 2004 July (Suppl);188(1A):1S-8S. |
| 34. | Briscoe DM, Dharnidharka VR, Isaacs C, Downing G, Prosky S, Shaw P, Parenteau NL, Hardin-Young J. The allogeneic response to cultured human skin equivalent in the hu-PBL-SCID mouse model of skin rejection. Transplantation 1999 Jun 27; 67(12): 1590-9 |
| 35. | Browse, N.L. and Burnand, K.G.: The Cause of Venous Ulceration. Lancet 2: 243-245, 1982 |
| 36. | Bui D, Ikeda C. Reconstruction of aplasia cutis congenita (group V) of the trunk in a newborn. Plast Reconstr Surg. 2003 May;111(6):2119-20 |
| 37. | Butmarc, J., T. Yufit, P. Carson, V. Falanga. Human Beta-Defensin-2 Expression is Increased in Chronic Wounds. Wound Repair Regen. 2004 Jul-Aug;12(4):439-43. |
| 38. | Cannon, Bradley C., Joan P. Cannon. Management of Pressure Ulcers. American Journal of Health-System Pharmacy, Vol 61, September 15, 2004. |
| 39. | Casasco, M., A. Casasco, A. Icaro Cornaglia, A. Farina, A. Calligaro. Differential Distribution of Elastic Tissue in Human Natural Skin and Tissue-Engineered Skin. J Mol Histol. 2004 May;35(4):421-8. |
| 40. | Cavorsi J, et al. Best Practices Algorithms for the use of a Bilayered Living Cell Therapy Apligraf in the Treatment of Lower Extremity Ulcers. Wound Rep Reg (2006) 14 102–109. |
| 41. | Cebon J, et al: Endogenous haemopoietic growth factors in neutropenia and infection. British Journal Haematology 86: 265-274, 1994 |
| 42. | Chang DW, Sanchez LA, Veith FJ, Wain RA, Okhi T, Suggs WD. Can a tissue engineered skin graft improve healing of lower extremity foot wounds after revascularization? Ann Vasc Surg. 2000 Jan; 14(1): 44-49. |
| 43. | Cohn, G.H.: Hyperbaric Oxygen Therapy. Promoting Healing in Difficult Cases. Postgrad. Med. 79(2): 89-92 (Feb. 1) 1986 |
| 44. | Collier M. The use of advanced biological and tissue-engineered wound products. Nurs Stand. 2006 Oct 25-31;21(7):68, 70, 72 passim. Review. |
| 45. | Culican SM, Custer PL. Repair of cicatricial ectropion in an infant with harlequin ichthyosis using engineered human skin. Am J Ophthalmol. 2002 Sep; 134(3): 442-3. |
| 46. | Curran MP, Plosker GL. Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers. BioDrugs 2002;16(6):439-55. |
| 47. | De SK, Reis ED, Kerstein MD. Wound treatment with human skin equivalent. J Am Podiatr Med Assoc. 2002 Jan; 92(1): 19-23 |
| 48. | De Imus, G, Golomb C, Wilkel C, et al. Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression. J Amer Acad of Derm 2001:44 (1) 61-66. |
| 49. | Dekker, P., WE Parish, MR Green. Protection by Food-derived Antioxidants from UVA1-induced Photodamage, Measured Using Living Skin Equivalents. Photochem Photobio. 2005 Feb 1 |
| 50. | Delfanian K, Davis MDP, Kavros SJ, Felty CL. Application of Living Skin Equivalent for the Treatment of Chronic Lower-Extremity Ulcers Recalcitrant to Conventional Therapeutic Methods. WOUNDS. March 2004 (16) number 3 105-108. |
| 51. | DeLoach, Ervin Daniel, MD, FACS, Fred G. Shealy, Jr., MD. Clinical Experience with Living Skin Equivalent in Two Free-Standing Wound Care Centers. Wounds 12(3):54-59, 2000. |
| 52. | Demidem, A., et al: Dissociation of Antigenicity and Immunogenicity of Neonatal Epidermal Allografts in the Mouse. Transplantation 49: 966-971, 1990 |
| 53. | Devereux, D.F., et al: A Study of Adriamycin-Reduced Wound Breaking Strength in Rats. An Evaluation by Light and Electron Microscopy, Induction of Collagen Maturation, and Hydroxyproline Content. Cancer 45: 2811-2815, 1980 |
| 54. | Dolynchuk K, Hull P, Guenther L, Sibbald RG, Brassard A, Cooling M, Delorme L, Gulliver W, Bourassa DH, Ho V, Kunimoto B, Overholt T, Papp K, Tousignant J. The role of Apligraf in the treatment of venous leg ulcers. Ostomy Wound Manag. 1999 Jan; 45(1): 34-43 |
| 55. | Donohue KG, Carson P, Iriondo M, Zhou L, Saap L, Gibson K, Falanga V. Safety and Efficacy of a Bilayered Skin Construct in Full-Thickness Surgical Wounds. The Journal of Dermatology Vol. 32: 626-631, 2005 |
| 56. | Dougherty, W.R. and Chalabian, J.R.: Skin Substitutes. West. J. Med. 162: 540-541, 1995 |
| 57. | Drosou A, Kirsner RS, Kato T, Mittal N, Al-Niami A, Miller B, Tzakis AG. Use of a bioengineered skin equivalent for the management of difficult skin defects after pediatric multivisceral transplantation. J Am Acad Dermatol. 2005 May;52(5):854-8. |
| 58. | Eaglstein WH, et al: A composite skin substitute (Graftskin) for surgical wounds. Dermatol Surg. 1995;21:839-843 |
| 59. | Eaglstein WH, Falanga V. Tissue engineering and the development of Apligraf, a human skin equivalent. Clin Ther. 1997 Sep-Oct; 19(5): 894-905. |
| 60. | Eaglstein WH, Falanga V. Tissue engineering and the development of Apligraf, a human skin equivalent. Cutis. 1998 Jul; 62(1 Suppl): 1-8 |
| 61. | Eaglstein WH, Falanga V. Tissue engineering and the development of Apligraf a human skin equivalent. Adv Wound Care 1998 Jul-Aug; 11(4 Suppl): 1-8. |
| 62. | Eaglstein W, et al: Acute excisional wounds treated with a tissue-engineered skin (Apligraf). Dermatologic Surgery, 1999;25: 195-201 |
| 63. | Edmonds M, Bates M, Doxford M, Gough A, Foster A. New treatments in ulcer healing and wound infection. Diabetes Metab Res Rev. 2000 Sep-Oct; 16 Suppl 1: S51-4. |
| 64. | Ehrlich HP. Understanding experimental biology of skin equivalent: from laboratory to clinical use in patients with burns and chronic wounds. Am J Surg. 2004 May;187(5A):29S-33S. Review. |
| 65. | Eisenbud D, Huang NF, Luke S, Silberklang M. Skin Substitutes and Wound Healing: Current Status and Challenges. WOUNDS 2004;16(1):2-17 |
| 66. | Espensen, EH, et al: Use of subatmospheric (VAC) therapy to improve bioengineered tissue grafting in diabetic foot wounds. Journal of the American Podiatr. Med. Assoc. 92(7): 395-397, 2002 |
| 67. | Fahey C. Experience with a new human skin equivalent for healing venous leg ulcers. J Vasc Nurs. 1998 Mar; 16(1): 11-5. |
| 68. | Falabella AF, Schachner JA Valencia JC, Eaglstein WH. The use of tissue-engineered skin (Apligraf) to treat a newborn with epidermolysis bullosa. Arch Dermatol. 1999 Oct;135(10):1219-22. |
| 69. | Falabella L and Eaglstein W: Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds. Arch. Dermatology 2000;136(10): 1225-1230. |
| 70. | Falanga V, Isaacs C, Paquette D, Downing G, Kouttab N, Butmarc J, Badiavas E, and Hardin Young J. Wounding of Bioengineered Skin: Cellular and Molecular Aspects After Injury. J. Invest Dermatol. 119:653-660, 2002. |
| 71. | Falanga, V. A Classification System for Evaluating Graft Appearance and Early Clinical Outcome of Bioengineered Skin in Human Wounds. Journal of Investigative Dermatology (2000) 114, 839. |
| 72. | Falanga, V. and Eaglstein, W.H.: The Trap Hypothesis of Venous Ulceration. Lancet 341: 1006-1008, 1993. |
| 73. | Falanga, V. and Eaglstein, W.H.: Leg and Foot Ulcers. A Clinician's Guide. London, Martin Dunitz Limited, 1995, pp. 1-182 |
| 74. | Falanga, V., et al: Rapid Healing of Venous Ulcers and Lack of Clinical Rejection with an Allogeneic Cultured Human Skin Equivalent. Arch. Dermatol. 134: 293-300, 1998. |
| 75. | Falanga V. Apligraf Treatment of Venous Ulcers and Other Chronic Wounds. Journal of Dermatol. 25: 812-817, 1998. |
| 76. | Falanga, V., et al: A New Cost Effective Therapy for the Treatment of Hard to Heal Venous Leg Ulcers. Wound Repair Regen. 6:3 (May-June) 1998. |
| 77. | Falanga V. How to Use Apligraf to Treat Venous Ulcers. Skin & Aging, February 1999:30-36. |
| 78. | Falanga V and Sabolinski M. A Bilayered Living Skin Construct (Apligraf®) Accelerates Complete Closure of Hard-to-Heal Venous Ulcers. Wound Repair and Regeneration, 7(4), July-August 1999: 201-207. |
| 79. | Falanga V, Sabolinski ML. Prognostic factors for healing of venous and diabetic ulcers. Wounds, 2000; 12(5 Suppl A):42A-46A. |
| 80. | Falanga V. Bioengineered skin. Wounds, 2000; 12(6 Suppl B):99B-105B. |
| 81. | Falanga VJ. Tissue engineering in wound repair. Adv Skin Wound Care 2000 May-Jun; 13(2 Suppl): 15-9 |
| 82. | Falanga V. Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair and Regeneration. Sep/Oct 2000; 8(5): 347-352 |
| 83. | Falanga, Vincent, MD, FACP. Venous Ulcers: New Treatment for an Old Disease. VHSJ, Veteran’s Health System Journal, July/August 1998: 41-48. |
| 84. | Falanga, V., et al: Wound Bed Score and its Correlation with Healing of Chronic Wounds. Dermatologic Therapy, Vol. 19, 2006, 383-390 |
| 85. | Fine JD: Skin bioequivalents and their role in the treatment of inherited epidermolysis bullosa. Arch. Dermatology 2000;136(10): 1259-1260. |
| 86. | Fivenson, David, MD; Kristi Robson, MD; Michelle Choucair, MD. Multimodal Therapy Approaching Difficult-to-Heal Wounds: Becaplermin in Combination with Sequential Living skin Equivalent Applications in a Series of Patients with Multifactorial Leg Ulcers. Wounds 2001; 13(6): 223-228 |
| 87. | Fivenson, DP, Scherschun L, Choueair M, KuKuruga D, Young J, Shwayder T. Graftskin therapy in epidermolysis bullosa. J Am Acad Dermatol 2003 June, 48 (6):886-92. |
| 88. | Fivenson DP, Scherschun L, Cohen LV. Apligraf in the treatment of severe mitten deformity associated with recessive dystrophic epidermolysis bullosa. Plast Reconstr Surg 2003 Aug; 112(2):584-8. |
| 89. | Fivenson D, Scherschun L. Clinical and economic impact of Apligraf for the treatment of nonhealing venous leg ulcers. Int J Dermatol. 2003 Dec;42(12):960-5. |
| 90. | Fivenson D and Falabella A. The use of Graftskin (Apligraf) for the Treatment of Epidermolysis Bullosa. Wounds, 2000;12(5 Suppl A):64A-71A. |
| 91. | Flores F, Eaglstein WA, Kirsner RS. Hydroxyurea-induced leg ulcers treated with Apligraf. Ann Intern Med. 2000 Mar 7; 132(5): 417-8 |
| 92. | Freedman G, Duron V, Brem H, Cean C, Tarnovskaya A. Pathogenesis and Treatment of pain in Patients with Chronic Wounds. Surgical Technology International XI. May 2003 pp. 168-178. |
| 93. | Fritschi, Cynthia. Preventitive Care of the Diabetic Foot. Nursing Clinics of North America. June 2001. 36:2 303-320. |
| 94. | Gohari S, Gambla C, Healey M, Spaulding G, Gordon KB, Swan J, Cook B, West DP, Lapiere JC. Evaluation of tissue-engineered skin (human skin substitute) and secondary intention healing in the treatment of full thickness wounds after Mohs micrographic or excisional surgery. Dermatol Surg. 2002 Dec;28(12):1107-14; discussion 1114 |
| 95. | Gordon S, Bui A. Human skin equivalent in the treatment of chronic leg ulcers in sickle cell disease patients. J Am Podiatr Med Assoc. 2003 May-Jun;93(3):240-1. |
| 96. | Greenberg JE, Falabella AF, Bello YM, and Schachner LA. Tissue Engineered Skin in the Healing of Wound Stumps from Limb Amputations Secondary to Purpura Fulminans. Pediatric Dermatology,, 2003; 20(2);169-172 |
| 97. | Griffiths M, Ojeh N, Livingstone R, Price R, Navsaria H. Survival of Apligraf in acute human wounds. Tissue Eng. 2004 Jul-Aug;10(7-8):1180-95. |
| 98. | Guerret S, Govignon E, Hartmann DJ, Ronfard V. Long-term remodeling of a bilayered living human skin equivalent (Apligraf) grafted onto nude mice: immunolocalization of human cells and characterization of extracellular matrix. Wound Repair Regen 2003 Jan-Feb;11(1):35-45. |
| 99. | Hansbrough, J.F., et al: Evaluation of Graftskin Composite Grafts on Full-Thickness Wounds on Athymic Mice. J. Burn Care Rehabil. 15: 346-353, 1994 |
| 100. | Hardin Young J, Teumer J, Kemp PD and Parenteau NL. Approaches to Transplanting Engineered Cells and Tissues. In: Lanza, R., Langer, R. and Chick, W., Editors. Principles of Tissue Engineering, R.G. Landes, 1997, ch. 20, pp. 297-307. |
| 101. | Hardin Young J, Teumer J, Ross RN and Parenteau NL. Approaches to Transplanting Engineered Cells and Tissues. In: Lanza, R., Langer, R. and Vacanti, J., Editors. Principles of Tissue Engineering, 2nd Edition, Academic Press, 2000, ch. 23, pp. 281-291. |
| 102. | Hardin-Young J and Parenteau NL. Bilayered Skin Constructs. In Atala and Lanza (Eds.),Methods of Tissue Engineering, Academic Press, 2002, pp. 1177-1188. |
| 103. | Harding K, Cutting K, Price P. The cost-effectiveness of wound management protocols of care. Br J Nurs. 2000 Oct; 9(19 Suppl): S6, S8, S10 passim. |
| 104. | Harding KG, Morris HL, Patel GK. Science, medicine and the future: healing chronic wounds. BMJ. 2002 Jan 19; 324(7330): 160-3. |
| 105. | Harrington C, Zagari MJ, Corea J, Klitenic J. A cost analysis of diabetic lower-extremity ulcers. Diabetes Care 2000 Sep;23(9):1333-8. |
| 106. | Hayes DW Jr, Webb GE, Mandracchia VJ and John KJ. Full-thickness burn of the foot: successful treatment with Apligraf. A case report. Clin Podiatr Med Surg, 2001 Jan; 18(1):179-88. |
| 107. | Horn WA. Graftskin heals an ulcer on an amputation stump. Dermatol Surg, 2000 Oct; 26(10):946-8. |
| 108. | Hunt TK, Hopf H, Hussain Z. Physiology of wound healing. Adv Skin Wound Care 2000 May-Jun; 13(2 Suppl): 6-11 |
| 109. | Hu, S. et al: Evaluation of Apligraf persistence and basement membrane restoration in donor site wounds: a pilot study. Wound Rep Reg (2006) 14 427–433 |
| 110. | Jansen DA, Asgari MM, Atillasoy ES, Milstone LM. Clinical and in vitro responses of bilayered skin construct (graftskin) to meshing. Arch Dermatol. 2002 Jun;138(6):843-4. |
| 111. | Jones JE, Nelson EA. Skin grafting for venous leg ulcers. Cochrane Database of Systematic Reviews 2000, Issue 2, Art. No.:CD001737 |
| 112. | Kerstein Morris D., et al: Development of a Severity Scale for Evaluating the Need for Graftskin in Nonhealing Ulcers. Adv in Skin Wound Care March/April 2002 15(2) p.66-71. |
| 113. | Kirsner RS. The Use of Apligraf in acute wounds. J Dermatol. 1998 Dec;25(12):805-11. |
| 114. | Kirsner RS, Fastenau J, Falabella A, Valencia I, Long R, Eaglstein WH. Clinical and economic outcomes with graftskin for hard-to-heal venous leg ulcers: a single-center experience. Dermatol Surg 2002;28:81-82 |
| 115. | Kirsner R, Falanga V, Fivenson D, Thibodeaux K, Cavorsi J, de la Pava D, Brem H, Golomb CA. Clinical Experience with a Human Skin Equivalent for the Treatment of Venous Leg Ulcers: Process and Outcomes. WOUNDS 1999; 11(6):137-144. |
| 116. | Kirsner RS. Report from the 61st Annual Society of Investigative Dermatology Meeting and from the International Dermatoepidemiology Association Meeting: A Wound Healing Perspective. WOUNDS 2000; 12(4):102-108. |
| 117. | Kirsner RS. The Science of Bilayered Cell Therapy. Supplement to Wounds, Sept. 2005 |
| 118. | Krasner D, Kane D. Chronic Wound Care: A Clinical Sourcebook for Healthcare Professionals. Second Edition. Health Management Publications, Inc. Wayne, PA 1997. |
| 119. | Kuroyanagi, Y, et al: Advances in cultured skin substitutes. Japanese Journal of Plastic and Reconstructive Surgery. 43(6): 571-580, 2000 |
| 120. | Langemo DK. Venous ulcers: etiology and care of patients treated with human skin equivalent grafts. J Vasc Nurs. 1999 Mar;17(1):6-11 |
| 121. | Lanning JC. DeLuca J, Hardin-Young, J. Effects of Immunoregulatory Cytokines on the Immunogenic Potential of the Cellular Components of a Bilayered Living Skin Equivalent. Tissue Engineering 1999. (5): 171-179. |
| 122. | Lazareth I. Local care and medical treatment for ischemic diabetic ulcers. J. Mal Vasc. 2002 June; 27(3):157-63. |
| 123. | Lee KH. Tissue-engineered human living skin substitutes: development and clinical application. Yonsei Med J. 2000 Dec; 41(6): 774-9. |
| 124. | Lee DK, Serkin AL. Carbon Dioxide Laser and Apligraf for a Painful Plantar Hypertrophic Scar. J of Amer. Pod. Med. Assoc. 2004 Jan/Feb;94(1):61-64. |
| 125. | Li VW, and Li WW. Rewriting the rulebook: a dermatologist's guide to off-label use of prescription drugs. Skin and Aging. May 2000: 28-36. |
| 126. | Long RE, Falabella AF, Valencia I, Eaglstein WH, Kirsner RS. Treatment of refractory, atypical lower extremity ulcers with tissue-engineered skin (Apligraf). Arch Dermatol. 2001 Dec; 137(12): 1660-1 |
| 127. | MacKay G. Bioactive wound healing, bioaesthetics and biosurgery: three pillars of product development. Interview with Geoff MacKay. Regen Med. 2006 Mar;1(2):169-74. |
| 128. | MacReady N. Bioengineered Skin helps Epidermolysis Bullosa. Dermatologic Surgery Feb 2004 vol. 35 number 2. |
| 129. | Maier JP, Lippitt C, Mooney EK. Use of tissue-engineered skin in the dermal atrophy patient with traumatic avulsion injuries. Ann Plast Surg. 2002 Jul;49(1):67-72; discussion 72. Erratum in: Ann Plast Surg 2002 Aug;49(2):214. |
| 130. | Margolis DJ, Berlin JA, Strom BL. Which Venous Leg Ulcers Will Heal with Limb Compression Bandages? Am J Med. 2000;109:15–19. |
| 131. | Martin LK, Kirsner RS. Ulcers caused by bullous morphea treated with tissue-engineered skin. Int J Dermatol. 2003 May;42(5):402-4. |
| 132. | Masseth R. Apligraf: A Promising New Wound Care Treatment for the 21st Century. J of Natinoal Assoc. Ortho Tech, Spring 2002:22-25. |
| 133. | Mathias SD, Prebil LA, Boyko WL, Fastenau J. Health-related quality of life in venous leg ulcer patients successfully treated with Apligraf: a pilot study. Adv Skin Wound Care, 2000; 13(2):76-8. |
| 134. | Medina J, de Brugerolle de Fraissinette, Chibout SD, Kolopp M, Kammermann R, Burtin P, Ebelin ME, Cordier A. Use of human skin equivalent Apligraf for in vitro assessment of cumulative skin irritation potential of topical products. Toxicol Appl Pharmacol. 2000 Apr 1; 164(1): 38-45 |
| 135. | Meaume S, Gemmen E. Cost-effectiveness of wound management in France: pressure ulcers and venous leg ulcers. J of Wound Care 2002 June; 11(6):219 |
| 136. | Milstone L, Asgari M, Schwartz P, and Hardin-Young J. Growth factor expression, healing, and structural characteristics of Graftskin (Apligraf®). Wounds, 2000 Sept; 12(5 Suppl A):12A-19A |
| 137. | Moneta G. Graftskin (Apligraf) in the treatment of venous leg ulcer: optimal application techniques. Wounds, 2000; 12(5 Suppl A):27A-32A. |
| 138. | Moneta G. et al, Skin Substitute Consensus Development Panel. Nonoperative Management of Venous Leg Ulcers: Evolving Role of Skin Substitutes. Vascular Surgery Vol 33, No 2, March/April 1999. |
| 139. | Mooney Eric K., Lippitt Craig, Reynolds Rick. Alternate Applications of Living Skin Equivalent. Wounds 2002; 14(7):257-265. |
| 140. | Mostow EN. Wound healing: a multidisciplinary approach for dermatologists. Dermatol Clin. 2003 Apr;21(2):371-87. |
| 141. | Muhart M, McFalls S, Kirsner RS, Elgart GW, Kerdel F, Sabolinski ML, Hardin-Young J, Eaglstein WH. Behavior of tissue-engineered skin: a comparison of a living skin equivalent, autograft, and occlusive dressing in human donor sites. Arch Dermatol. 1999 Aug; 135(8): 913-8. |
| 142. | Mustoe, Thomas A. MD; Han, Hongshik MD. The Effect of New Technologies on Plastic Surgery. Archives of Surgery, Volume 134(11) November 1999 pp 1178-1183 |
| 143. | Nichols Don. The New Science of Wound Care. Contemporary Long Term Care. Nov. 1995 |
| 144. | Noel B. Economic assessment of Apligraf for the treatment of venous leg ulcers. Wound Repair Regen. 2001 Jan-Feb; 9(1): 60. |
| 145. | Nolte, C.J.M., et al: Ultrastructural Features of Composite Skin Cultures Grafted onto Athymic Mice. J. Anat. 185: 325-333, 1994 |
| 146. | O'Donnell TF, Lau J. A systematic review of randomized controlled trials of wound dressings for chronic venous ulcer. J Vasc Surg 2006;44:1118-25. |
| 147. | Osborne CS, Schmid P. Epidermal-dermal interactions regulate gelatinase activity in Apligraf, a tissue-engineered human skin equivalent. Br J Dermatol. 2002 Jan; 146(1): 26-31. |
| 148. | Ozerdem OR, Wolfe SA and Marshall D. Use of Skin Substitutes in Pediatric Patients. J Craniofac Surg.;14(4):517-20, 2003. |
| 149. | Parenteau, N.L., et al: Epidermis Generated in vitro: Practical Considerations and Applications. J. Cell Biochem. 45: 245-251, 1991 |
| 150. | Parenteau, N. et al, Biological and Physical Factors Influencing the Successful Engraftment of a Cultured Human Skin Substitute. Biotechnology and Bioengineering 1996, Vol. 52, pp. 3-14. |
| 151. | Parenteau N, Sabolinski M, Mulder G and Rovee D. Wound Research. In: Krasner D., Kane D. Chronic Wound Care, Second Edition. Wayne, PA, Health Management Publications, Inc., 1997, pp. 389-395. |
| 152. | Parenteau N. Skin: The First Tissue-Engineered Products - The Organogenesis Story. Scientific American, April 1999. |
| 153. | Parenteau NL, Hardin Young J and Ross RN. Skin. In: Lanza, R., Langer, R. and Vacanti, J., Editors. Principles of Tissue Engineering, 2nd Edition, Academic Press, 2000, pp. 879-890. |
| 154. | Pennoyer JW, et al: Ulcers associated with polyarteritis nodosa treated with bioengineered human skin equivalent (Apligraf). Journal of the American Academy of Dermatology 2002;46(1): 145 |
| 155. | Petrova N, Edmonds M. Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. Review |
| 156. | Pham, H.T., et al: Evaluation of a Human Skin Equivalent for the Treatment of Diabetic Foot Ulcers in a Prospective, Randomized, Clinical Trial. Wounds 11(4): 79-86 (July-Aug.) 1999. |
| 157. | Pham, HT. Wound Care in Diabetic Foot Ulceration. WOUNDS 2000; 12(6 Suppl B):82B-89B. |
| 158. | Pham HT, Rich J, Veves A. Wound Healing in Diabetic Foot Ulceration: A Review and Commentary. WOUNDS 2000; 12(4):79-81. |
| 159. | Phillips J, Rockwell WB. Surgical treatment of recessive dystrophic epidermolysis bullosa in the hand: use of tissue-engineered skin (Apligraf). Ann Plast Surg 2003 Apr; 50(4):441-2. |
| 160. | Phillips TJ. New Skin for Old. Arch of Dermatol. March 1998 (134): 344-349. |
| 161. | Phillips TJ, Manzoor J, Rojas A, Isaacs C, Carson P, Sabolinski M, Young J, Falanga V. The longevity of a bilayered skin substitute after application to venous ulcers. Arch Dermatol. 2002 Aug;138(8):1079-81. |
| 162. | Phillips TJ. Current approaches to venous ulcers and compression. Dermatol Surg. 2001 Jul;27(7):611-21. |
| 163. | Phillips TJ. Successful methods of treating leg ulcers. The tried and true, plus the novel and new. Postgrad Med. 1999 May 1;105(5):159-61, 165-6, 173-4 passim. |
| 164. | Pollak R. Use of Graftskin (Apligraf) in diabetic foot ulcers: case presentations. Wounds, 2000; 12(5 Suppl A):37A-41A. |
| 165. | Redekop WK, McDonnell J, Verboom P, Lovas K, Kalo Z. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics 2003;21(16):1171-83. |
| 166. | Saap, Liliana J., Kevin Donohue, Vincent Falanga. Clinical Classification of Bioengineered Skin Use and Its Correlation with Healing of Diabetic and Venous Ulcers. Dermatol Surg, 30th ed.: 1095-1100, 2004. |
| 167. | Saap Liliana J., Falanga Vincent. Debridement Performance index and its correlation with complete closure of diabetic foot ulcers. Wound Rep Reg 2002; 10: 354-359 |
| 168. | Sabolinski, M.L., et al: Cultured Skin as a Smart Material for Healing Wounds: Experience in Venous Ulcers. Biomaterials 17: 311-320, 1996 |
| 169. | Sabolinski ML, Veves A. Graftskin (Apligraf) in neuropathic diabetic foot ulcers. Wounds, 2000; 12(5 Suppl A):33A-36A. |
| 170. | Sabolinski ML and Bilbo PR. The Clinical Experience of Bioengineered Skin Products. In Falanga, V. (Ed.), Cutaneous Wound Healing, Martin Dunitz, 2001, pp. 411-431. |
| 171. | Sabolinski ML, et al: Graftskin in the treatment of diabetic foot ulcers resulted in significantly lower rates of amputations. Oral Presentation. Wound-healing Society, May 2001 |
| 172. | Sams HH, Chen J, King LE. Graftskin treatment of difficult to heal diabetic foot ulcers: one center's experience. Dermatol Surg. 2002 Aug;28(8):698-703. |
| 173. | Schachner, L and Eaglstein, W: Baby is pioneer patient for new use of skin. Am. Med. News 1999;42(5): 1 |
| 174. | Schmid P. Immunohistologic characterization of Graftskin (Apligraf®). Wounds, 2000 Sept; 12(5 Suppl A):4A-11A. |
| 175. | Schmid P, Grenet O, Medina J, Chibout S, Osborne C, and Cox D. An intrinsic antibiotic mechanism in wounds and tissue-engineered skin. J of Invest Derm, 2001 March; 116:471-472. |
| 176. | Schober-Flores C. Epidermolysis bullosa: the challenges of wound care. Dermatol Nurs. 2003 Apr;15(2):135-8, 141-4. |
| 177. | Schonfeld, W.H., et al: An economic assessment of Apligraf for the treatment of hard-to-heal venous leg ulcers. Wound Repair and Regeneration 8(4): 251-257, Jul-Aug, 2000 |
| 178. | Shealy FG, DeLoach ED. Experience with the Use of Apligraf to Heal Complicated Surgical and Nonsurgical Wounds in a Private Practice Setting. Advances in Skin & Wound Care 2006 Vol. 19 No. 6:310-22. |
| 179. | Sheehan P, et al. Percent Change in Wound Area of Diabetic Foot Ulcers Over a 4-Week Period Is a Robust Predictor of Complete Healing in a 12-Week Prospective Trial. Diabetes Care 26:1879–1882, 2003 |
| 180. | Shen, John T., MD, Linda Zhou, MD, Vincent Falanga, MD. Bioengineered Skin. International Journal of Cosmetic Surgery and Aesthetic Dermatology. Vol 5, No. 1, 2003. |
| 181. | Sher, S.E., et al: Acceptance of Allogeneic Fibroblasts in Skin Equivalent Transplants. Transplantation 36: 552-557, 1983 |
| 182. | Sheridan, R.L., et al: Artificial Skin in Massive Burns – Results to Ten Years. Eur. J. Plast. Surg. 17: 91-93, 1994 |
| 183. | Sibbald RG, Torrance GW, Walker V, Attard C, MacNeil P. Cost-effectiveness of Apligraf in the treatment of venous leg ulcers. Ostomy Wound Manage. 2001 Aug; 47(8): 36-46. |
| 184. | Sibbald RG, Apligraf Living Skin Equivalent for Healing Venous and Chronic Wounds. Jour of Cutaneous Medicine and Surgery. 1998, 3(suppl 1): S1-24-S1-28. |
| 185. | Sieggreen MY, Kline RA. Recognizing and managing venous leg ulcers. Adv Skin Wound Care. 2004 Jul-Aug;17(6):302-11; quiz 312-3. Review. |
| 186. | Soo, C., et al: The Immunogenicity of Bovine Collagen Implants. J. Dermatol. Surg. Oncol. 19: 431-434, 1993 |
| 187. | Steinberg J. How you can use Apligraf to treat diabetic foot ulcers? Podiatry Today, 2000 September. |
| 188. | Steinberg J, et al: A Cost Analysis of a Living Skin Equivalent in the Treatment of Diabetic Foot Ulcers. Wounds 2002 14(4):142-149. |
| 189. | Steinberg J and Ho T. Apligraf: how effective is it? Podiatry Today, 2001 September. |
| 190. | Steinberg J. Putting Bilayered Cell Therapy to Use. Wounds, Supplement 2005 September. |
| 191. | Still J and Craft-Coffman B. Graftskin (Apligraf) in the management of thermal injury. Wounds, 2000; 12(5 Suppl A):58A-63A. |
| 192. | Streit M, Braathen LR. Apligraf – a living human skin equivalent for the treatment of chronic wounds. Int J Artif Organs. 2000 Dec;25(12):831-3. |
| 193 | Streit M, et al: Ulcerative sarcoidosis successfully treated with Apligraf. Dermatology 2001;202(4): 367-370 |
| 194. | Streit M, et al: Wound Closure in 101 Chronic leg ulcers after application of Apligraf. |
| 195. | Tarlow M, et al: Effective management of difficult surgical defects using tissue engineered skin. Dermatologic Surgery 2001;27: 71-74 |
| 196. | Teumer J, Hardin-Young J and Parenteau NL. Tissue Engineered Skin. In: Patrick, Charles W., Jr., Mikos, Antonios G. and McIntire, Larry V., Eds. Frontiers in Tissue Engineering. Elsevier Science Ltd., 1998. |
| 197. | Theobald, V.A., et al: Neutral Allografts–Lack of Allogeneic Stimulation by Cultured Human Cells Expressing MHC Class I and Class II Antigens. Transplantation 55: 128-133, 1993 |
| 198. | Tomic-Canic M. Keratinocyte Cross-Talks in Wounds. Wounds, Supplement 2005 September |
| 199. | Treadwell T. Management of Saphenous Vein Harvest Wound Complications Following Coronary Artery Bypass Grafting. Wounds 2003; 15(3):83-91. |
| 200. | Trent JF, Kirsner RS. Tissue-engineered skin: Apligraf, a bi-layered living skin equivalent. Int J Clin Pract. 1998 Sep;52(6):408-413. |
| 201. | Trent, JT, Kirsner RS. Epidermolysis Bullosa: Identification and Treatment. Advances in Skin Wound Care. Nov 2003:16(6):284-90. |
| 202. | Valencia IC, Falabella A, Kirsner RS, and Eaglstein WH. Chronic venous insufficiency and venous leg ulceration. J Amer Acad Dermatol, 2001 Mar;44(3):401-21. |
| 203. | Veves A., et al: Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 24(2):290-295 (Feb.) 2001 |
| 204. | Waugh H, Sherratt J. Modeling the effects of treating diabetic wounds with engineered skin substitutes. Wound Repair Regen 2007 Jul-Aug;15(4):556-65 |
| 205. | Waymack, P., et al: The effect of a tissue engineered bilayered living skin analog, over meshed split-thickness autografts on the healing of excised burn wounds. Burns (UK) 26: 609-619, 2000 |
| 206. | Wickware P. Progress from a fragile start. Nature 2000 Jan 27; 403: 466. |
| 207. | Wilkins, L.M., et al: Development of a Bilayered Living Skin Construct for Clinical Applications. Biotechnol. Bioeng. 43: 747-756, 1994 |
| 208. | Wilkins LM and Parenteau NL. Bioengineered Skin: Manufacturing, Safety, and Quality Control In Falanga V, (Ed.) Cutaneous Wound Healing, Martin Dunitz, 2001, pp. 399-410. |
| 209. | Wong T, McGrath JA, Navsaria H. The role of fibroblasts in tissue engineering and regeneration. Br J Dermatol. 2007 Jun;156(6):1149-1155. |
| 210. | Woo K, Ayello EA, Sibbald RG. The Edge Effect: Current Therapeutic Options to Advance the Wound Edge. Advances in Skin & Wound Care Feb 2007; 20:99-117; quiz 118-9. |
| 211. | Worcester, Sharon. Apligraf Shows Promise in Building Vaginal Wall in Rokitansky Syndrome. Ob.Gyn. News Vol. 40, No. 13. August, 2005. |
| 212. | Zaulyanov-Scanlan L, Kirsner RS. A Review of a Bi-Layered Living Cell Treatment (Apligraf) in the Treatment of Venous Leg Ulcers and Diabetic Foot Ulcers. Clinical Interventions in Aging 2007:2(1) 1-6. |
| 213. | Zieske, J.D., et al: Basement Membrane Assembly and Differentiation of Cultured Corneal Cells: Importance of Culture Environment and Endothelial Cell Interaction. Exp. Cell Res. 214: 621-633, 1994 |